Unfortunately, their clinical use is complicated by hepatic steatosis, degradation of hepatic LDL receptors via the LXR-IDOL (inducible degrader of the LDL receptor) pathway, and/or unexplained neurological side effects (26, 38). Here, MYLIP is linked to Hepatic steatosis.